Oncogenes and Male Breast Carcinoma: c-erbB-2 and p53 Coexpression Predicts a Poor Survival

• DOI: 10.1200/jco.2000.18.16.2948
• Publication Date: 2017-02-24T09:19:48Z
• Authors: Achille Pich; Elena Margaria; Luigi Chiusa
• Keywords: Univariate analysis; ErbB; Breast carcinoma

PURPOSE: To investigate the prognostic value of biomarkers in male breast carcinoma (MBC). PATIENTS AND METHODS: Fifty patients (mean age, 62.2 years) with invasive ductal were retrospectively studied. All received surgery; 35 had adjuvant postoperative therapy. The median follow-up was 59 months (range, 1 to 230 months). c-myc, c-erbB-2, p53, and bcl-2 proteins immunohistochemically detected on sections from formalin-fixed, paraffin-embedded tissues using 9E11, CB11, DO7, 124 monoclonal antibodies (mAbs). Estrogen, progesterone, androgen receptors specific mAbs. Cell proliferation assessed by MIB-1 mAb. RESULTS: In univariate analysis, p53 protein overexpression significantly correlated prognosis. survival 107 for c-myc–negative 52 c-myc–positive (P = .01), 96 c-erbB-2–negative 39 c-erbB-2–positive .02), 100 p53-negative 33 p53-positive .0008). Tumor histologic grade tumor size patient age at diagnosis .03), scores .0004) also value. multivariate only c-erbB-2 immunoreactivity retained independent significance. nine who did not express alive after 58 months, whereas none 14 expressing both survived 61 .0002). CONCLUSION: Overexpression may be regarded as an additional factor MBC. combination can stratify into different risk groups.